Lymphomas, which are frequently subdivided into Hodgkin’s disease and non-Hodgkin’s lymphoma, represent one of the more curable cancers that present as a solid tumor. Unfortunately, most patients cannot be cured with conventional chemotherapy, therefore new techniques have been developed including high-dose chemotherapy and autotransplantation. Non-Hodgkin’s lymphoma was one of the first illnesses to be tested using the new methods and initial encouraging results in relapsed lymphoma led to the testing of high-dose chemotherapy with autotransplantation as a primary therapy for patients with lymphomas. Encouraging results have been obtained in several randomized trials. Studies of the treatment of lymphoma have identified several principles related to the application of autotransplantation, which may be relevant to other solid tumors. Autotransplantation is likely to be of benefit only when using active chemotherapeutic agents that can be escalated in dose and when myelosuppression is the dose-limiting toxicity. Chemotherapy-responsive tumors are obvious targets for autotransplantation, whereas chemotherapy-resistant tumors are unlikely to benefit. Other factors that should be taken into account when selecting patients for high-dose chemotherapy regimens include the extent of disease, preceding therapy and the performance status of the patient.

Keywords:
Autotransplantation, High-dose chemotherapy, Lymphoma, Solid tumor
1.
The Non-Hodgkin’s Lymphoma Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 1982;49:2112–2135.
2.
Lennert K, Mohri N, Stein H, Keiserling E: The histopathology of malignant lymphoma. Br J Haematol 1975;31(suppl):193–203.
3.
Lennert K: Malignant Lymphomas Other Than Hodgkin’s Disease. New York, Springer, 1978.
4.
Stansfeld A, Diebold J, Noel H, Kapanci Y, Kelenyi G, Sundstrom C, Lennert K, van Unnik JA, Mioduszewska O: Updated Kiel classification of lymphomas. Lancet 1988;i:292–293.
5.
Harris JN, Jaffe ES, Stein H: A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.
6.
The Non-Hodgkin’s lymphoma Classification Project: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997;89:3909–3918.
7.
Ziegler JL, Morrow RH, Fass L, Kyalwazi SK, Carbone PP: Treatment of Burkitt’s tumor with cyclophosphamide. Cancer 1970;26:474–478.
8.
Levitt M, Marsh JC, DeConti R, Mitchell MS, Skeel RT, Farber LR, Bertino JR: Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 1972;29:630–636.
9.
DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC: Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet 1975;i:248–250.
10.
Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr: The treatment of indolent lymphomas: Watchful waiting v aggressive combined modality treatment. Semin Hematol Suppl 1988;2:11–16.
11.
Osgood EE, Riddle MC, Mathews TJ: Aplastic anemia treated with daily transfusions and intravenous marrow: Case report. Ann Intern Med 1939;13:357–367.
12.
Lorenz E, Uphoff D, Reid TR, Shelton E: Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst 1951;12:197–201.
13.
Thomas ED, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD: Bone-marrow transplantation. N Engl J Med 1975;292:832–843, 895–902.
14.
Appelbaum FR, Herzig GP, Ziegler JL, Graw RG, Levine AS, Deisseroth AB: Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978;52:85–95.
15.
Korbling M, Dorken B, Ho AD, Pezzutto A, Hunstein W, Fliedner TM: Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt’s lymphoma. Blood 1986;67:529–532.
16.
Kessinger A, Armitage JO, Landmark JD, Weisenburger DD: Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells. Exp Hematol 1986;14:192–196.
17.
Gianni AM, Siena S, Bregni M: Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989;ii:580–585.
18.
Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth AB, Cleary K, Champlin R, van Besein K, Andersson B, Korbling M: Allogeneic blood stem cell transplantation in advanced hematologic cancers. Bone Marrow Transplant 1997;19:455–460.
19.
Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, Colombat P, Goldstone AH, Gorin NC, Flesh M: High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin’s lymphoma. N Engl J Med 1987;316:1493–1498.
20.
Colombat P, Gorin N-C, Lemonnier M-P, Binet C, Laporte JP, Douay L, Desbois I, Lopez M, Lamagnere JP, Najman A: The role of autologous bone marrow transplantation in 46 adult patients with non-Hodgkin’s lymphomas. J Clin Oncol 1990;8:630–637.
21.
Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW: The treatment of progressive non-Hodgkin’s lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 1990;75:831–838.
22.
Petersen FB, Appelbaum FR, Hill R, Fisher LD, Bigelow CL, Sanders JE, Sullivan KM, Bensinger WI, Witherspoon RP, Storb R: Autologous marrow transplantation for malignant lymphoma: A report of 101 cases from Seattle. J Clin Oncol 1990;8:638–647.
23.
Weisdorf DJ, Haake R, Miller WJ, McGlave PB, LeBien TW, Vallera DA, Lasky LC, Kim TH, Peterson BA, Ramsay NK: Autologous bone marrow transplantation for progressive non-Hodgkin’s lymphoma: Clinical impact of immunophenotype and in vitro purging. Bone Marrow Transplant 1991;8:135–142.
24.
Lazarus HM, Crilley P, Ciobanu N, Creger RJ, Fox RM, Shina DC, Bulova SI, Gucalp R, Cooper BW, Topolsky D: High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma. J Clin Oncol 1992;10:1682–1689.
25.
Gulati S, Yahalom J, Acaba L, Reich L, Motzer R, Crown J, Toia M, Igarashi T, Lemoli R, Hanninen E: Treatment of patients with relapsed and resistant non-Hodgkin’s lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation. J Clin Oncol 1992;10:936–941.
26.
Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC, Gordon B, Armitage JO: High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin’s lymphoma. J Clin Oncol 1993;11:1846–1851.
27.
Rapoport AP, Rowe JM, Kouides PA, Duerst RA, Abboud CN, Liesveld JL, Packman CH, Eberly S, Sherman M, Tanner MA: One hundred autotransplants for relapsed or refractory Hodgkin’s disease and lymphoma: Value of pretransplant disease status for predicting outcome. J Clin Oncol 1993;11:2351–2361.
28.
Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP: Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin’s lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993;11:1085- 1091.
29.
Weaver CH, Petersen FB, Appelbaum FR, Bensinger WI, Press O, Martin P, Sandmaier B, Deeg HJ, Hansen JA, Brunvand M: High-dose fractionated total-body irradiation, etoposide, and cyclophosphamide followed by autologous stem-cell support in patients with malignant lymphoma. J Clin Oncol 1994;12:2559–2566.
30.
Horning SJ, Negrin RS, Chao NJ, Long GD, Hoppe RT, Blume KG: Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 1994;12:2552–2558.
31.
van Besien K, Tabocoff J, Rodriguez M, Andersson B, Mehra R, Przepiorka D, Dimopoulos M, Giralt S, Suki S, Khouri I: High-dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: Durable complete remission, but a high rate of regimen-related toxicity. Bone Marrow Transplant 1995;15:549–555.
32.
Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. J Clin Oncol 1995;13:588–595.
33.
Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995;333:1540–1545.
34.
Gulati SC, Shank B, Black P, Yopp J, Koziner B, Straus D, Filippa D, Kempin S, Castro-Malsapina H, Cunningham I: Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988;6:1303–1313.
35.
Milpied N, Ifrah N, Kuentz M, Maraninchi D, Colombat P, Blaise D, Harousseau JL: Bone marrow transplantation for adult poor prognosis lymphoblastic lymphoma in first complete remission. Br J Haematol 1989;73:82–87.
36.
Baro J, Richard C, Calavia J, Gonzales San-Miguel JD, Bello Fernandez C, Alsar MJ, Gomez-Casares MT, Iriondo A, Conde E, Hermosa V: Autologous bone marrow transplantation as consolidation therapy for non-Hodgkin’s lymphoma patients with poor prognostic features. Bone Marrow Transplant 1991;8:283–289.
37.
Nademanee A, Schmidt GM, O’Donnell MR, Snyder DS, Parker PA, Stein A, Smith E, Lipsett JA, Sniecinski I, Margolin K: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: A pilot study. Blood 1992;80:1130–1134.
38.
Freedman AS, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, Soiffer RJ, Spector N, Grossbard M, Robertson MJ: Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin’s lymphoma in first remission: A pilot study. J Clin Oncol 1993;11:931–936.
39.
Jackson GH, Lennard AL, Taylor PRA, Carey P, Angus B, Lucraft H, Evans RG, Proctor SJ: Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin’s lymphoma in first complete remission. Br J Cancer 1994;70:501–505.
40.
Sweetenham JW, Proctor SJ, Blaise D, De Laurenzi A, Pearce R, Taghipour G, Goldstone AH: High-dose therapy and autologous bone marrow transplantation in first complete remission for adult patients with high-grade non-Hodgkin’s lymphoma: The EBMT experience. Ann Oncol 1994;5(suppl 2):S155–S159.
41.
Fanin R, Silvestri F, Geromin A, Cerno M, Infanti L, Zaja F, Barillari G, Savignano C, Rinaldi C, Damiani D, Buffoli A, Biffoni F, Baccarini M: Primary systemic CD30 (Ki-1)-positive anaplastic large cell lymphoma of the adult: Sequential intensive treatment with the F-MACHOP regimen (± radiotherapy) and autologous bone marrow transplantation. Blood 1996;87:1243–1248.
42.
Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ, Deakin DP, Ryder D, Wilkinson PM, Crowther D: Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin’s lymphoma. J Clin Oncol 1996;14:586–592.
43.
Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, Ravagnani F, Valagussa P, Bonadonna G: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–1297.
44.
Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P, Bosly A, Dupriez B, Nouvel C, Tilly H, Lederlin P, Biron P, Briere J, Gaulard P, Reyes F: Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin’s lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 1997;15:1131–1137.
45.
Shipp MA, Harrington DP, Anderson JR: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;329:987–994.
46.
Reyes F, Lepage E, Morel P, Lederlin P, Coiffier B, Tilly H, Bosly A, Gabarre J, Brière J, Fillet G, Molina T, Gisselbrecht C: Failure of first-line high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: Updated results of the randomized LNH93-3 study. Blood 1997;90:594A.
47.
Verdonck LF, van Putten WLJ, Hagenbeek A, Schoutten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JM, van Oers RH, Haak HL: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995;332:1045–1051.
48.
Martelli M, Vignetti M, Zinzani PL, Gherlinzoni F, Meloni G, Fiacchini M, De Sanctis V, Papa G, Martelli MF, Calabresi F, Tura S, Mandelli F: High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin’s lymphoma with partial response to front-line chemotherapy: A prospective randomised Italian multicenter study. J Clin Oncol 1996;14:534–542.
49.
Rohatiner AZS, Johnson PWM, Price CGA, Arnott SJ, Amess JA, Norton AJ, Dorey E, Adams K, Whelan JS, Matthews J: Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma. J Clin Oncol 1994;12:1177–1184.
50.
Colombat PH, Donadio D, Fouillard L, Milpied N, Tilly H, Pico J, Abgrall JF, Coiffier B, Herbrecht R, Philip T: Value of autologous bone marrow transplantation in follicular lymphoma: A France Autogreffe retrospective study of 42 patients. Bone Marrow Transplant 1994;13:157–162.
51.
Cervantes F, Shu XO, McGlave PB, Ramsay NK, Miller WJ, Kersey JH, Weisdorf DJ: Autologous bone marrow transplantation for non-transformed low-grade non-Hodgkin’s lymphoma. Bone Marrow Transplant 1995;16:387–392.
52.
Bastion Y, Price P, Haioun C, Sonet A, Salles G, Marolleau JP, Espinouse D, Reyes F, Grisselbrecht C, Coiffier B: Intensive therapy with peripheral blood progenitor cell transplantation in 60 patients with poor-prognosis follicular lymphoma. Blood 1995;86:3257–3262.
53.
Bierman P, Vose J, Anderson J, Bishop MR, Kessinger A, Armitage JO: High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin’s lymphoma. J Clin Oncol 1997;15:445–450.
54.
Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Mauch P, Takvorian T, Soiffer R, Blake K, Yeap B: Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin’s lymphoma. Blood 1991;77:2524–2529.
55.
Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Nadler LM: High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood 1996;88:2780–2786.
56.
Bierman P, Anderson J, Vose J, Freeman M, Bishop M, Kessinger A, Armitage J: High-dose chemotherapy with autologous hematopoietic rescue for Hodgkin’s disease (HD) following first relapse after chemotherapy. ASCO Proc 1993;12:366.
57.
Dave BV, Pickering DL, Hess MM, Weisenberger DD, Armitage JO, Sanger WG: Rearrangements of chromosome band 1p36 and loss of putative tumor suppressor gene in non-Hodgkin’s lymphoma. Proc 17th Int Cancer Congr 1998, p 365.
58.
Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: A randomised trial. J Clin Oncol 1995;13:2483–2489.
59.
Crown J: High-dose chemotherapy of solid tumours. Ann Oncol 1995;6(suppl 1):S11–S15.
60.
Broun ER, Nichols CR, Turns M, Williams SD, Loehrer PJ, Roth BJ, Lazarus HM, Einhorn LH: Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer 1994;73:1716–1720.
61.
Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Curé H, Heron JF, Chevallier B, Fargeot P, Kramar A: Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial. Eur Urol 1993;23:213–217.
62.
Peters WP, Jones RB, Vredenburgh J, Shpall EJ, Hussein A, Elkorsy M, Rubin P, Ross M, Berry D: A large prospective randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM) (abstract). Proc Am Soc Clin Oncol 1996;15:121.
63.
Letendre L, Noel P, Tefferi A, Litzow M, White WL, Gastineau D, Li CY, Schroeder G: Treatment of unfavourable myelodysplastic syndrome with low dose cytosine arabinoside (LD-ARA-C) and trans-retinoic acid (TRA) (abstract 115). Proc Am Soc Clin Oncol 1998;17:30a.
64.
Stadmauer EA: Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: The Philadelphia Intergroup Study (abstract 1). Proc Am Soc Clin Oncol 1999;18:1a.
65.
Lotz J-P, Curé H, Janvier M, Morvan F, Asselain B, Guillemot M, Laadem A, Maraninchi D, Gisselbrecht C, Roché H and the PEGASE Group: High-dose chemotherapy (HD-CT) with haematopoietic stem cell transplantation (HSCT) for metastatic breast cancer (MBC): Results of the French protocol PEGASE 04 (abstract 161). Proc Am Soc Clin Oncol 1999;18:43a.
66.
Peters W, Rosner G, Vredenburgh J, Shpall E, Crump M, Richardson P, Marks L, Cirrinclone C, Wood W, Henderson I, Hurd D, Norton L for CALGB, SWOG and NCIC: A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13 (abstract 2). Proc Am Soc Clin Oncol 1999;18:1a.
67.
Rodenhuis S, Richel DJ, can der Wall E, Schornagel JH, Baars JW, Koning CCE, Peterse JL, Borger JH, Nooijen AJ, Bakx R, Dalesio O, Rutgers E: Randomised trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 1998;352:515–521.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.